In a groundbreaking trial, the daily pill daraxonrasib has shown to nearly double the survival time for patients with advanced pancreatic cancer. Targeting the mutated KRAS gene, which is present in over 90% of pancreatic tumors, daraxonrasib resulted in a median survival of 13.2 months, significantly longer than the 6.6 months seen with traditional chemotherapy. The trial involved 500 patients from North America, Europe, and Asia, all of whom had advanced cancer that had spread to other organs. Notably, patients taking daraxonrasib experienced fewer serious side effects, with only 43.6% reporting severe reactions compared to 57.5% for those on chemotherapy. Experts, including Rachna Shroff from the University of Arizona Cancer Centre, hailed these results as transformative for patients with KRAS mutations. Anna Jewell from Pancreatic Cancer UK emphasized the importance of making such promising treatments available in the UK, where approximately 11,500 cases are diagnosed annually, leading to 10,200 deaths. The study's findings suggest that daraxonrasib not only improves survival but also helps control cancer progression more effectively.